SLC7A11 and inflammatory bowel disease: CD44v9 contributes to cell proliferation and survival by reducing anti-proliferative reactive oxygen species (ROS) levels through interacting with and regulating xCT, a cystine transporter.9 Sulfasalazine, a drug developed to treat inflammatory bowel disease and rheumatoid arthritis, was identified as a xCT-selective inhibitor.